Assessment report - European Medicines Agency
administration of antidiabetic drugs. Although initially effective, currently available oral antidiabetic agents often fail to maintain long-term glycaemic control or are associated with side effects, often including weight gain, which may limit their use. Hence, there is a need for new
Download Assessment report - European Medicines Agency
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Natural products to drugs: natural product derived ...
esa.ipb.ptREVIEW NPR www.rsc.org/npr Natural products to drugs: natural product derived compounds in clinical trials Mark S. Butler* MerLion Pharmaceuticals, 1 Science Park ...
Specialty Pharmacy Drug List
magellanrx.com• Orphan or Ultra-Orphan drugs • Medications that are included in a specialty therapeutic drug class strategy Generics: Lower case italic. For example, dexferrum Brands: All capital letters. For example, HUMIRA QL: Quantity Limits apply under some benefits. Check your plan document for coverage details.
Data exclusivity, market protection, orphan and paediatric ...
www.ema.europa.euEuropean orphan legislation Lack of appropriate treatment –‘ Patients suffering from rare conditions should be entitled to the same level of treatments as other patients’ Market often economically not interesting Lack in return of investment •1983 –US Orphan Drugs Act •1993 –Japanese legislation for Orphan Drugs
Instructions for Form 6765 (Rev. December 2020)
www.irs.govdrugs for certain rare diseases, you can elect to claim the orphan drug credit for these expenses instead of the research credit. See Form 8820, Orphan Drug Credit. See section 41 and Regulations sections 1.41-2 and 1.41-4 for other definitions and special rules. Eligible Small Business (For Purposes of Offsetting AMT Only)
Pharmaceutical Reimbursement and Pricing in Germany
www.oecd.orgFor orphan drugs, additional therapeutic benefit is assumed by virtue of marketing authorisation without reference to an appropriate comparator in Germany for as long as annual SHI expenditure for the entire population treated with the drug remains below EUR 50 million (Bouslouk, 2016). Manufacturers are exempted from
Lists of medicinal products for rare diseases in Europe*
www.orpha.netThe orphan medicinal products list in Europe, with orphan designation and European marketing authorisations, is determined by cross-referencing the list of medicinal